Sign inJoin waitlistJoin the waitlist

Tracy L. Rose

Internal Medicine · Unc Physicians and Associates

Credentials: · · · ·

History

Research

Renal Cell Carcinoma: A Review
Review · JAMA · 2024 · First of 2 authors · 332 citations
Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline
Systematic review or meta-analysis · Journal of Clinical Oncology · 2022 · 288 citations
Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience
British Journal of Cancer · 2021 · Co-first of 18 authors · 149 citations

Matthew Milowsky
42 papers
Marc Bjurlin
22 papers
William Kim
20 papers
Sara Wobker
14 papers
Angela Smith
11 papers
Hung-Jui Tan
9 papers · 5 as a resident
Matthew Nielsen
8 papers
CO
Chelsea Osterman
6 papers · 5 as a fellow
Eric Wallen
6 papers
Kathryn Gessner
6 papers · 3 as a fellow
Young Whang
6 papers
Michael Woods
5 papers

Grants

Selective Histone Deacetylase Inhibition with Entinostat to Enhance the Anti-Tumor Immune Response to Immune Checkpoint Inhibition in Urothelial Cancer
National Cancer Institute · K08
Contact PI · $786.9K · Univ of North Carolina Chapel Hill
2020–2024

Clinical trials

PRO-VISION: Patient Reported Outcomes-Based Monitoring of VEGF-Inhibitor Side Effects in ONcology
Principal investigator · Active not recruiting
UNC Lineberger Comprehensive Cancer Center
2022–2031
Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer
Principal investigator · Active not recruiting · Phase 2
UNC Lineberger Comprehensive Cancer Center
2020–2026
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2025–2037
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
Site PI · Recruiting · Phase 2
NRG Oncology
2023–2033